DaBomb Protein Biotech Corp.

TPEX:6578 Stock Report

Market Cap: NT$1.3b

DaBomb Protein Biotech Dividends and Buybacks

Dividend criteria checks 1/6

DaBomb Protein Biotech is a dividend paying company with a current yield of 2.85%.

Key information

2.8%

Dividend yield

0%

Buyback Yield

Total Shareholder Yield2.8%
Future Dividend Yieldn/a
Dividend Growth-17.0%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per shareNT$0.550
Payout ratio489%

Recent dividend and buyback updates

Recent updates

Should You Be Impressed By DaBomb Protein's (GTSM:6578) Returns on Capital?

Feb 17
Should You Be Impressed By DaBomb Protein's (GTSM:6578) Returns on Capital?

DaBomb Protein (GTSM:6578) Has A Somewhat Strained Balance Sheet

Jan 13
DaBomb Protein (GTSM:6578) Has A Somewhat Strained Balance Sheet

Is DaBomb Protein Corp. (GTSM:6578) A Risky Dividend Stock?

Dec 09
Is DaBomb Protein Corp. (GTSM:6578) A Risky Dividend Stock?

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: 6578 has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: 6578 has only been paying a dividend for 8 years, and since then payments have fallen.


Dividend Yield vs Market

DaBomb Protein Biotech Dividend Yield vs Market
How does 6578 dividend yield compare to the market?
SegmentDividend Yield
Company (6578)2.8%
Market Bottom 25% (TW)1.8%
Market Top 25% (TW)4.5%
Industry Average (Personal Products)4.8%
Analyst forecast (6578) (up to 3 years)n/a

Notable Dividend: 6578's dividend (2.85%) is higher than the bottom 25% of dividend payers in the TW market (1.78%).

High Dividend: 6578's dividend (2.85%) is low compared to the top 25% of dividend payers in the TW market (4.55%).


Earnings Payout to Shareholders

Earnings Coverage: With its high payout ratio (489.4%), 6578's dividend payments are not well covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its high cash payout ratio (651.9%), 6578's dividend payments are not well covered by cash flows.


Discover strong dividend paying companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 08:51
End of Day Share Price 2024/12/19 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

DaBomb Protein Biotech Corp. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution